Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance

Advances in Enzyme Regulation

Volumn 46, Issue 1, 2006, Pages 249-279

  McCubrey, James A ^a   Steelman, Linda S ^a   Abrams, Steven L ^a   Lee, John T ^a   Chang, Fumin ^a   Bertrand, Fred E ^a   Navolanic, Patrick M ^a   Terrian, David M ^a   Franklin, Richard A ^a   D'Assoro, Antonio B ^b   Salisbury, Jeffrey L ^b   Mazzarino, Maria Clorinda ^c   Stivala, Franca ^c   Libra, Massimo ^c  

^a EAST CAROLINA UNIVERSITY   (United States)

^b Mayo Clinic   (United States)

^c UNIVERSITY OF CATANIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PTEN PROTEIN, HUMAN;

ARTICLE; CELL TRANSFORMATION; DRUG ANTAGONISM; DRUG RESISTANCE; ENZYMOLOGY; GENETICS; HUMAN; NEOPLASM; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; DRUG RESISTANCE, NEOPLASM; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; MAP KINASE KINASE KINASES; NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; SIGNAL TRANSDUCTION;

EID: 33748063941     PISSN: 00652571     EISSN: None     Source Type: Book Series    
DOI: 10.1016/j.advenzreg.2006.01.004     Document Type: Article

References (117)

1. Akula S.M., Ford P.W., Whitman A.G., Hamden K.H., Shelton J.G., and McCubrey J.A. Raf promotes human herpesvirus-8 (HHV-8/KSHV) infection. Oncogene 23 (2004) 5227-5241
2. Akula S.M., Ford P.W., Whitman A.G., Hamden K.E., Bryan B.A., Cook P.P., et al. B-Raf dependent expression of vascular endothelial growth factor-A in Kaposi's sarcoma-associated herpesvirus infected human B cells. Blood 105 (2005) 4516-4522
3. Alessi D.R., Saito Y., Campbell D.G., Cohen P., Sithanandam G., Rapp U., et al. Identification of the sites in MAP kinase kinase-1 phosphorylated by p74raf-1. EMBO J 13 (1994) 1610-1619
4. Alexia C., Fallot G., Lasfer M., Schweizer-Groyer G., and Groyer A. An evaluation of the role of insulin-like growth factors (IGF) and of type-I IGF receptor in signaling in hepatocarcinogenesis and in the resistance of hepatocarcinoma cells against drug-induced apoptosis. Biochem Pharmacol 68 (2004) 1003-1015
5. Allan L.A., Morrice N., Brady S., Magee G., Pathak S., and Clarke P.R. Inhibition of caspase-9 through phosphorylation at Thr 125 by ERK MAPK. Nat Cell Biol 7 (2003) 647-654
6. Allen L.F., Sebolt-Leopold J., and Meyer M.B. CI-1040 (PD184352), a targeted signal transduction inhibitor of MEK (MAPKK). Sem Oncol 30 (2003) 105-116
7. Barnard D., Diaz B., Clawson D., and Marshall M. Oncogenes, growth factors and phorbol esters regulate Raf-1 through common mechanisms. Oncogene 17 (1998) 1539-1547
8. Basu A., and Haldar S. Microtubule-damaging drugs triggered bcl2 phosphorylation-requirement of phosphorylation on both serine-70 and serine-87 residues of bcl2 protein. Int J Oncol 13 (1998) 659-664
9. Blagosklonny M.V. The mitogen-activated protein kinase pathway mediates growth arrest or E1A-dependent apoptosis in SKBR3 human breast cancer cells. Int J Cancer 78 (1997) 511-517
10. Blagosklonny M.V. Drug-resistance enables selective killing of resistant leukemia cells: exploiting of drug resistance instead of reversal. Leukemia 13 (1999) 2031-2035
11. Blagosklonny M.V. Hsp-90-associated oncoproteins: multiple targets of geldanamycin and its analogs. Leukemia 16 (2002) 455-462
12. Blagosklonny M.V., Schulte T., Nguyen P., Trepel J., and Neckers L.M. Taxol-induced apoptosis and phosphorylation of Bcl-2 protein involves c-Raf-1 and represents a novel c-Raf-1 signal transduction pathway. Cancer Res 56 (1996) 1851-1854
13. Blagosklonny M.V., Prabhu N.S., and El-Deiry W.S. Defects in p21WAF1/CIP1, Rb and c-myc signaling in phorbol ester-resistant cancer cells. Cancer Res 57 (1997) 320-325
14. Blalock W.L., Weinstein-Oppenheimer C., Chang F., Hoyle P.E., Wang X.-Y., Algate P.A., et al. Signal transduction, cell cycle regulatory, and anti-apoptotic pathways regulated by IL-3 in hematopoietic cells: possible sites for intervention with anti-neoplastic drugs. Leukemia 13 (1999) 1109-1166
15. Blalock W.L., Pearce M., Steelman L.S., Franklin R.A., McCarthy S.A., Cherwinski H., et al. A conditionally active form of MEK1 results in autocrine transformation of human and mouse hematopoietic cells. Oncogene 19 (2000) 526-536
16. Brummer T., Shaw P.E., Reth M., and Misawa Y. Inducible gene deletion reveals different roles for B-Raf and Raf-1 in B-cell antigen receptor signalling. EMBO J 21 (2002) 5611-5622
17. Busca R., Abbe P., Mantous F., Aberdam E., Peyssonnaux C., Eychene A., et al. Ras mediates the cAMP-dependent activation of extracellular signal-regulated in melanocytes. EMBO J 19 (2000) 2900-2910
18. Cip1 induced by Raf is associated with increased Cdk4 activity in hematopoietic cells. Oncogene 20 (2001) 4354-4364
19. Chang F., Steelman L.S., and McCubrey J.A. Raf-induced cell cycle progression in human TF-1 hematopoietic cells. Cell Cycle 1 (2002) 220-226
20. Chang F., Steelman L.S., Lee J.T., Shelton J.G., Navolanic P.M., Blalock W.L., et al. Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention. Leukemia 17 (2003) 1263-1293
21. Chang F., Lee J.T., Navolanic P.M., Steelman J.G., Blalock W.L., Franklin R.A., et al. Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy. Leukemia 17 (2003) 590-603
22. Cioffi C.L., Garay M., Johnston J.F., McGraw K., Boggs R.T., Hreniuk B.D., et al. Selective inhibition of A-Raf and C-Raf mRNA expression by antisense oligodeoxynucleotides in Rat vascular smooth muscle cells: role of A-Raf and C-Raf in serum-induced proliferation. Mol Pharmacol 51 (1997) 383-389
23. Corbit K.C., Trakul N., Eves E.M., Diaz B., Marshall M., and Rosner M.R. Activation of Raf-1 signaling by protein kinase C through a mechanism involving Raf kinase inhibitory protein. J Biol Chem 278 (2003) 13061-13068
24. Crdone M.H., Roy N., Stennicke H.R., Salvesen G.S., Franke T.F., Stanbridge E., et al. Regulation of cell death protease caspase 9 by phosphorylation. Science 282 (1998) 1318-1321
25. Davis H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S., et al. Mutations of the BRAF gene in human cancer. Nature 417 (2002) 949-954
26. Davis J.M., Weinstein-Oppenheimer C.R., Steelman L.S., Navolanic P.N., Hu W., Konopleva M., et al. Raf-1 and Bcl-2 induce distinct and common pathways which contribute to breast cancer drug resistance. Clin Cancer Res 9 (2003) 1161-1170
27. Deng X., Ruvolo P., Carr B., and May Jr. W.S. Survival function of ERK1/2 as an IL-3 activated, staurosporine-resistant Bcl2 kinases. Proc Natl Acad Sci USA 97 (2000) 1578-1583
28. Deng X., Kornblau S.M., Ruvulo P.P., and May Jr. W.S. Regulation of Bcl2 phosphorylation and potential significance for leukemic cell chemoresistance. JNCI Monogr 28 (2001) 30-37
29. Dhillon A.S., Meikle S., Yazici Z., Eulitz M., and Kolch W. Regulation of Raf-1 activation and signaling by dephosphosphorylation. EMBO J 21 (2002) 64-71
30. Diaz B., Barnard D., Filson A., MacDonald S., King A., and Marshall M. Phosphorylation of Raf-1 serine 338-serine 339 is an essential regulatory event for Ras-dependent activation and biological signaling. Mol Cell Biol 17 (1997) 4509-4516
31. Du J., Cai S.H., Shi Z., and Nagase F. Binding activity of H-Ras is necessary for in vivo inhibition of ASK1 activity. Cell Res 14 (2004) 148-154
32. Fabian J.R., Daar I.O., and Morrison D.K. Critical tyrosine residues regulate the enzymatic and biological activity of Raf-1 kinase. Mol Cell Biol 13 (1993) 7170-7179
33. Fantl W.J., Muslin A.J., Kikuchi A., Martin J.A., MacNicol A.M., Gross R.W., et al. Activation of Raf-1 by 14-3-3 proteins. Nature 371 (1994) 612-614
34. Flotho C., Valcamonica S., Mach-Pascual S., Schmahl G., Corral L., Ritterbach J., et al. RAS mutations and clonality analysis in children with juvenile myelomonocytic leukemia (JMML). Leukemia 13 (1999) 32-37
35. Ford P.W., Hamden K.E., Whitman A.G., McCubrey J.A., and Akula S.M. Vascular endothelial growth factor augments human Herpesvirus-8 (HHV-8/KSHV) infection. Cancer Biol Ther 3 (2004) 876-881
36. Fransen K., Klinntenas M., Osterstrom A., Dimberg J., Monsteis H.J., and Soderkvist P. Mutation analysis of the B-Raf, A-Raf and Raf-1 genes in human colorectal adenocarcinomas. Carcinogensis 25 (2004) 527-533
37. Fry M.J. Phosphoinositide 3-kinase signalling in breast cancer: how big a role might it play?. Breast Cancer Res 3 (2001) 304-312
38. Fu Z., Smith P.C., Zhang L., Rubin M.A., Dunn R.L., Yao Z., et al. Effects of raf kinase inhibitor protein on suppression of prostate cancer metastasis. JNCI 95 (2003) 878-889
39. Garnett M.J., and Marais R. Guilty as charged: B-Raf is a human oncogene. Cancer Cell 6 (2004) 313-319
40. Guan K.L., Figueroa C., Brtva T.R., Zhu T., Taylor J., Barber T.D., et al. Negative regulation of the serine/threonine kinase B-Raf by Akt. J Biol Chem 275 (2000) 27354-27359
41. Haldar S., Jena N., and Croce C.M. Antiapoptosis potential of bcl-2 oncogene by dephosphorylation. Biochem Cell Biol 72 (1994) 455-462
42. Hall-Jackson C.A., Eyers P.A., Cohen P., Goedert M., Boyle F.T., Hewitt N., et al. Paradoxical activation of Raf by a novel Raf inhibitor. Chem Biol 6 (1999) 559-568
43. Hamden K.E., Ford P.W., Whitman A.G., McCubrey J.A., and Akula S.M. Raf induced vascular endothelial growth factor augments Kaposi's Sarcoma-associated herpesvirus (KSHV/HHV-8) infection. J Virol 78 (2004) 13381-13390
44. Hamden K.E., Ford P.W., Whitman A.G., Shelton J.G., McCubrey J.A., and Akula S.M. Raf and VEGF: emerging therapeutic targets in Kaposi's Sarcoma-associated herpesviurs infection and angiogenesis in hematopoietic and non-hematopoietic tumors. Leukemia 19 (2005) 18-26
45. Heimbrook D.C., Huber H.E., Stirdivant S.M., Claremon D., Liverton N., Patrick D.R., et al. Identification of potent, selective kinase inhibitors of Raf. Proc Am Assoc Cancer Res 39 (1998) 558
46. Hindley A., and Kolch W. Extracellular signal regulated kinase (ERK)/mitogen activated protein kinase (MAPK)-independent functions of Raf kinases. J Cell Sci 115 (2002) 1575-1581
47. Hoyle P.E., Moye P.W., Steelman L.S., Blalock W.L., Franklin R.A., Pearce M., et al. Differential abilities of the Raf family of protein kinases to abrogate cytokine dependency and prevent apoptosis in murine hematopoietic cells by a MEK1-dependent mechanism. Leukemia 14 (2000) 642-656
48. Jucker M., Sudel K., Horn S., Sickel M., Wegner W., Fiedler W., et al. Expression of a mutated form of the p85alpha regulatory subunit of phosphatidylinositol 3-kinase in a Hodgkin's lymphoma-derived cell line (CO). Leukemia 16 (2002) 894-901
49. Keller E.T., Fu Z., Yeung K., and Brennan M. Raf kinase inhibitor protein: a prostate cancer metastasis suppressor gene. Cancer Lett 207 (2004) 131-137
50. Kim S.H., Lee S.H., Kwak N.H., Kang C.D., and Chung B.S. Effect of the activated Raf protein kinase on the human multidrug resistance 1 (MDR1) gene promoter. Cancer Lett 98 (1996) 199-205
51. Kobayashi S., Boggon T.J., Dayaram T., Janne P.A., Kocher O., Meyerson M., et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352 (2005) 830-832
52. Kolch W. To be or not to be: a question of B-Raf. Trends Neurosci 21 (2001) 498-500
53. Kolch W., Heidecker G., Kochs G., Hummel R., Vahidi H., Mischak H., et al. Protein kinase Cα activates RAF-1 by direct phosphorylation. Nature 364 (1993) 249-252
54. Krasilnikov M., Adler V., Fuchs S.Y., Dong Z., Haimovitz-Friedman A., Herlyn M., et al. Contribution of phosphatidylinositol 3-kinase to radiation resistance in human melanoma cells. Mol Carcinog 24 (1999) 64-69
55. Lee Jr. J.T., and McCubrey J.A. The Raf/MEK/ERK signal transduction cascade as a target for chemotherapeutic intervention. Leukemia 16 (2002) 486-507
56. Lee Jr JT, McCubrey JA. BAY 43-9006 Bayer. Curr Opin Invest drugs 2003;4:757-63.
57. Lee J.T., Steelman L.S., and McCubrey J.A. PI3K activation leads to MRP1 expression and subsequent chemoresistance in advanced prostate cancer cells. Cancer Res 64 (2004) 8397-8404
58. Lee J.T., Steelman L.S., and McCubrey J.A. Modulation of Raf/MEK/ERK pathway in prostate cancer drug resistance. Int J Oncol (2005) 1637-1645
59. Lee J.W., Yoo N.J., Soung Y.H., Kim H.S., Park W.S., Kim S.Y., et al. BRAF mutations in non-Hodgkin's lymphoma. Br J Cancer 89 (2003) 1958-1960
60. Lee J.W., Soung Y.H., Park W.S., Kim S.Y., Nam S.W., Min W.S., et al. BRaf mutations in acute leukemias. Leukemia 18 (2004) 170-172
61. Libra M., Malaponte G., Navolanic P.M., Gangemi P., Bevelacqua V., Proietti L., et al. Analysis of BRAF mutation in primary and metastatic melanoma. Cell Cycle 4 (2005) 1382-1384
62. Lin J., Adam R.M., Santiestevan E., and Freeman M.R. The phosphatidylinositol 3′-kinase pathway is a dominant growth factor-activated cell survival pathway in LNCaP human prostate carcinoma cells. Cancer Res 59 (1999) 2891-2897
63. Lin X., Bohle A.S., Dohrmann P., Leuschner I., Schulz A., Kremer B., et al. Overexpression of phosphatidylinositol 3-kinase in human lung cancer. Langenbecks Arch Surg 386 (2001) 293-301
64. Lloyd A.C., Obermuller F., Staddon S., Barth C.F., McMahon M., and Land H. Cooperating oncogenes converge to regulate cyclin/Cdk complexes. Genes Dev 11 (1997) 663-677
65. Luo Z., Tzivion G., Belshaw P.J., Vavvas D., Marshall M., and Avruch J. Oligomerization activates c-Raf-1 through a Ras-dependent mechanism. Nature 383 (1996) 181-185
66. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350 (2004) 2129-2139
67. Lyons J.F., Wilhelm S., Hibner B., and Bollag G. Discovery of a novel Raf kinase inhibitor. Endocr Rel Cancer 8 (2001) 219-225
68. INK4b. Mol Cell Biol 20 (2000) 2915-2925
69. Marais R., Light Y., Paterson H.F., Mason C.S., and Marshall C.J. Differential regulation of Raf-1, A-Raf, and B-Raf by oncogenic ras and tyrosine kinases. J Biol Chem 272 (1997) 4378-4383
70. Martinez-Lorenzo M.J., Anel A., Monleon I., Sierra J.J., Pineiro A., Naval J., et al. Tyrosine phosphorylation of the p85 subunit of phosphatidylinositol 3-kinase correlates with high proliferation rates in sublines derived from the Jurkat leukemia. Int J Biochem Cell Biol 32 (2000) 435-445
71. Mason C.S., Springer C.J., Cooper R.G., Superti-Furga G., Marshall C.J., and Marais R. Serine and tyrosine phosphorylations cooperate in Raf-1, but not B-Raf activation. EMBO J 18 (1999) 2137-2148
72. Mazzucchelli C., Vantaggiato C., Ciamei A., Fasano S., Pakhotin P., Krezel W., et al. Knockout of ERK1 MAP kinase enhances synaptic plasticity in the striatum and facilitates striatal-mediated learning and memory. Neuron 34 (2002) 807-820
73. McCarthy S.A., Samuels M.L., Pritchard C.A., Abraham J.A., and McMahon M. Rapid induction of heparin-binding epidermal growth factor/diphtheria toxin receptor expression by Raf and Ras oncogenes. Genes Dev 9 (1995) 1953-1964
74. McCarthy S.A., Chen D., Yang B.S., Garcia Ramirez J.J., Cherwinski H., Chen X.R., et al. Rapid phosphorylation of Ets-2 accompanies mitogen-activated protein kinase activation and the induction of heparin-binding epidermal growth factor gene expression by oncogenic Raf-1. Mol Cell Biol 17 (1997) 2401-2412
75. McCubrey J.A., Steelman L.S., Hoyle P.E., Blalock W.L., Weinstein-Oppenheimer C., Franklin R.A., et al. Differential abilities of activated Raf oncoproteins to abrogate cytokine-dependency, prevent apoptosis and induce autocrine growth factor synthesis in human hematopoietic cells. Leukemia 12 (1998) 1903-1929
76. McCubrey J.A., Lee J.T., Steelman L.S., Blalock W.L., Moye P.W., Chang F., et al. Interactions between the PI3K and Raf signaling pathways can result in the transformation of hematopoietic cells. Cancer Det Prev 25 (2001) 375-393
77. Mercer K.E., and Pritchard C.A. Raf proteins and cancer: B-Raf is identified as a mutational target. Biochim Biophys Acta 1653 (2003) 25-40
78. Milella M., Kornblau S.M., Estrov Z., Carter B.Z., Lapillone H., Harris D., et al. Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia. J Clin Invest 108 (2001) 851-859
79. Milella M., Estrov Z., Kornblau S.M., Carter B.Z., Konopleva M., Tari A., et al. Synergistic induction of apoptosis by simultaneous disruption of the Bcl-2 and MEK/MAP pathways in acute myelogenous leukemia. Blood 99 (2002) 3461-3464
80. Mitenberger R.J., Farham P.J., Smith D.E., Stommell J.M., and Cornwell M.M. v-Raf activates transcription of growth-responsive promoters via GC-rich sequences that bind the transcription factor Sp1. Cell Growth Differ 6 (1995) 549-556
81. Neckers L. Hsp90inhibitors as novel cancer chemotherapeutic agents. Trends Mol Med 8 (2002) S55-S61
82. Neshat M.S., Raitano A.B., Wang H.G., Reed J.C., and Sawyers C.L. The survival function of the BCR-ABL oncogene is mediated by Bad-dependent and -independent pathways: roles for phosphatidylinositol 3-kinase and Raf. Mol Cell Biol 20 (2000) 1179-1186
83. Nicholson K.M., and Anderson N.G. The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal 14 (2002) 381-395
84. O'Neill E., Rushworth L., Baccarini M., and Kolch W. Role of the kinase MST2 in suppression of apoptosis by the proto-oncogene product Raf-1. Science 306 (2004) 2267-2270
85. Pedersen-Bjergaad J., Christiansen D.H., and Andersen M.K. Genetic pathways in t-MDS and t-AML, a revised model. Blood Suppl 818 (2004)
86. Peyssonnaux C., Provot S., Felder-Schmittbuhl M.P., Calothy G., and Eychéne A. Induction of postmitotic neuroretina cell proliferation by distinct Ras downstream signaling pathways. Mol Cell Biol 20 (2000) 7068-7079
87. Pouyssegur J., Volmat V., and Lenormand P. Fidelity and spatio-temporal control in MAP kinase (ERKs) signaling. Biochem Pharm 64 (2002) 755-763
88. Pritchard C.A., Bolin L., Slattery R., Murray R., and McMahon M. Post-natal lethality and neurological and gastrointestinal defects in mice with targeted disruption of the A-Raf protein kinase gene. Curr Biol 6 (1996) 614-617
89. Rajagopalan H., Bardelli A., Lengauer C., Kinzler K.N., Vogelstein B., and Velculesccu V.E. Tumorigenesis: Raf/Ras oncogenes and mismatch-repair status. Nature 418 (2002) 934
90. Ravi R.K., Weber E., McMahon M., Williams J.R., Baylin S., Mal A., et al. Activated Raf-1 causes cell cycle arrest in small cell lung cancer cells. J Clin Invest 101 (1998) 153-159
91. Ravi R.K., McMahon M., Yangang Z., Williams J.R., Dillehay L.E., Nelkin B.C., et al. Raf-1-induced cell cycle arrest in LNCap human prostate cancer cells. J Cell Biochem 72 (1999) 458-469
92. Rommel C., Clarke B.A., Zimmermann S., Nuñez L., Rossman R., Reid K., et al. Differentiation stage-specific inhibition of the Raf-MEK-ERK pathway by Akt. Science 286 (1999) 1738-1741
93. Salomoni P., Wasik M.A., Riedel R.F., Reiss K., Choi J.K., Skorski T., et al. Expression of constitutively active Raf-1 in the mitochondria restores antiapoptotic and leukemogenic potential of a transformation-deficient BCR/ABL mutant. J Exp Med 187 (1998) 1995-2007
94. Sanders M.R., Lu H., Walker F., Sorbad S., and Dainiak N. The Raf-1 protein mediates insulin-like growth factor-induced proliferation of erythroid progenitor cells. Stem Cells 16 (1998) 200-207
95. Shelton J.G., Steelman L.S., Lee J.T., Knapp S.L., Blalock W.L., Moye P.M., et al. Effects of the Raf/MEK/ERK and PI3K signal transduction pathways on the abrogation of cytokine dependence and prevention of apoptosis in hematopoietic cells. Oncogene 24 (2003) 2478-2492
96. Shelton J.G., Moye P.W., Steelman L.S., Blalock W.L., Lee J.T., Franklin R.A., et al. Differential effects of kinase cascade inhibitors on neoplastic and cytokine-mediated cell proliferation. Leukemia 17 (2003) 1765-1782
97. Shelton J.G., Chang F., Lee J.T., Franklin R.A., Steelman L.S., and McCubrey J.A. B-Raf and insulin synergistically prevent apoptosis and induce cell cycle progression in hematopoietic cells. Cell Cycle 3 (2004) 189-196
98. Shelton J.G., Steelman L.S., Abrams S.L., Bertrand F.E., Franklin R.A., McMahon M., et al. The epidermal growth factor receptor gene family as a target for therapeutic intervention in numerous cancers-what's genetics got to do with it?. Exp Opin Ther Targets 9 (2005) 1009-1030
99. Shelton J.G., Steelman L.S., Abrams S.L., White E.R., Akula S.M., Bertrand F.E., et al. Conditional EGFR promotes cell cycle progression and prevention of apoptosis in the absence of autocrine cytokines. Cell Cycle 4 (2005) 822-830
100. Sordella R., Bell D.W., Haber D.A., and Settleman J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 305 (2004) 1163-1167
101. Steelman L.S., Pohnert S.C., Shelton J.G., Franklin R.A., Bertrand F.E., and McCubrey J.A. JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia 18 (2004) 189-218
102. Steelman L.S., Bertrand F.E., and McCubrey J.A. The complexity of PTEN: mutation, marker and potential target for therapeutic intervention. Exp Opin Ther Targets 8 (2004) 537-550
103. Stirewalt D.L., Kopecky K.J., Meshinchi S., Appelbaum F.R., Slovak M.L., Willman C.L., et al. FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia. Blood 97 (2001) 3589-3595
104. Wadewitz A.G., Winer M.A., and Wolgemuth D.J. Developmental and cell lineage specificity of raf family gene expression in mouse. Oncogene 8 (1993) 1055-1062
105. Wan P.T., Garnett M.J., Ros S.M., Lee S., Niculescu-Duvaz D., Good V.M., et al. Mechanism of activation of the Raf-MEK signaling pathway by oncogenic mutations of B-Raf. Cell 116 (2004) 856-867
106. Weinstein-Oppenheimer C.R., Henríquez-Roldán C.F., Davis J., Navolanic P.M., Saleh O.A., Steelman L.S., et al. Role of the Raf signal transduction cascade in the in vitro resistance to the anticancer drug doxorubicin. Clin Cancer Res 7 (2001) 2892-2907
107. Wojnowski L., Zimmer A.M., Bec T.W., Hahn H., Bernal R., Rapp U.R., et al. Endothelial apoptosis in Braf-deficient mice. Nat Genet 16 (1997) 293-297
108. Cip. Mol Cell Biol 19 (1997) 5598-5611
109. Workman P. Altered states: selectively drugging the Hsp90 cancer chaperone. Trends Mol Med 10 (2004) 47-51
110. Yan J., Roy S., Apolloni A., Lane A., and Hancock J.F. Ras isoforms vary in their ability to activate Raf-1 and phosphoinositide 3-kinase. J Biol Chem 273 (1998) 24052-24056
111. Yen A., Williams M., Platko J.D., Der C., and Hisaka M. Expression of activated Raf accelerates cell differentiation and RB protein down-regulation but not hypophosphorylation. Eur J Cell Biol 65 (1994) 103-113
112. Yeung K., Seitz T., Li S., Janosch P., McFerran B., Kaiser C., et al. Suppression of Raf-1 kinase activity and MAP kinase signaling by RKIP. Nature 401 (1999) 173-177
113. Yu C., Dai Y., Dent P., and Grant S. Coadministration of UCN-01 with MEK1/2 inhibitors potently induces apoptosis in BCR/ABL+ leukemia cells sensitive and resistant to STI571. Cancer Biol Ther 1 (2002) 674-682
114. Yuen S.T., Davies H., Chan T.L., Ho J.W., Bignell G.R., Cox C., et al. Similarity of the phenotypic patterns associated with B-Raf and KRAS mutations in colorectal neoplasia. Cancer Res 62 (2002) 6451-6455
115. Zebisch A., Staber P.B., Fischereder K., Bodner C., Hiden K., Linkesch W., et al. Two novel activating germiline mutations of the c-Raf proto-oncogene predisposing to solid tumors and therapy related acute myeloid leukemia. Blood Suppl 920 (2004)
116. Zha J., Harada H., Yang E., Jockel J., and Korsmeyer S.J. Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not Bcl-XL. Cell 87 (1996) 589-592
117. Zhang B.H., Tang E.D., Zhu T., Greenberg M.E., Vojtek A.B., and Guan K.L. Serum- and glucocorticoid-inducible kinase SGK phosphorylates and negatively regulates B-Raf. J Biol Chem 276 (2001) 31620-31626